Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Bell

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
Lancet (London, England)|February 21, 2017
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trialDavid Cameron, Martine J Piccart-Gebhart, Richard D Gelber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2014
Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01)Evandro de Azambuja, Marion J Procter, Dirk J van Veldhuisen, et al.
Science Translational Medicine|June 24, 2026
<i>SPP1</i><sup>hi</sup> macrophages in fibrin niches promote hyperplastic tissue remodeling in rheumatoid arthritis synoviumIan Mantel, Haoxuan Zhang, Juan Vargas, et al.
Lancet (London, England)|January 9, 2007
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialIan Smith, Marion Procter, Richard D Gelber, et al.
The Lancet. Oncology|March 1, 2011
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trialLuca Gianni, Urania Dafni, Richard D Gelber, et al.
The Lancet. Oncology|August 13, 2013
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trialDavid Cameron, Julia Brown, Rebecca Dent, et al.
Lancet (London, England)|July 23, 2013
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trialAron Goldhirsch, Richard D Gelber, Martine J Piccart-Gebhart, et al.
BJU International|February 26, 2026
The PRAGMATIC pathway - PRostate cancer diAGnosis and MAnagement Triage In Clinical careAbhishek Sharma, Teresa Campbell, Sagar Kanabar, et al.
BJU International|January 15, 2021
Local anaesthetic transperineal (LATP) prostate biopsy using a probe-mounted transperineal access system: a multicentre prospective outcome analysisJ Francisco Lopez, Angus Campbell, Altan Omer, et al.
The New England Journal of Medicine|October 21, 2005
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancerMartine J Piccart-Gebhart, Marion Procter, Brian Leyland-Jones, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Lancet (London, England)|February 21, 2017
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trialDavid Cameron, Martine J Piccart-Gebhart, Richard D Gelber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2014
Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01)Evandro de Azambuja, Marion J Procter, Dirk J van Veldhuisen, et al.
Science Translational Medicine|June 24, 2026
<i>SPP1</i><sup>hi</sup> macrophages in fibrin niches promote hyperplastic tissue remodeling in rheumatoid arthritis synoviumIan Mantel, Haoxuan Zhang, Juan Vargas, et al.
Lancet (London, England)|January 9, 2007
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialIan Smith, Marion Procter, Richard D Gelber, et al.
The Lancet. Oncology|March 1, 2011
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trialLuca Gianni, Urania Dafni, Richard D Gelber, et al.
The Lancet. Oncology|August 13, 2013
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trialDavid Cameron, Julia Brown, Rebecca Dent, et al.
Lancet (London, England)|July 23, 2013
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trialAron Goldhirsch, Richard D Gelber, Martine J Piccart-Gebhart, et al.
BJU International|February 26, 2026
The PRAGMATIC pathway - PRostate cancer diAGnosis and MAnagement Triage In Clinical careAbhishek Sharma, Teresa Campbell, Sagar Kanabar, et al.
BJU International|January 15, 2021
Local anaesthetic transperineal (LATP) prostate biopsy using a probe-mounted transperineal access system: a multicentre prospective outcome analysisJ Francisco Lopez, Angus Campbell, Altan Omer, et al.
The New England Journal of Medicine|October 21, 2005
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancerMartine J Piccart-Gebhart, Marion Procter, Brian Leyland-Jones, et al.
Pageof 10